Zydus Lifesciences Limited has received the Establishment Inspection Report (EIR) from the USFDA for its API manufacturing facility located in Ambernath, Maharashtra.
The USFDA inspection was conducted from 10 February 2025 to 14 February 2025.
The inspection concluded with NIL observations.
The EIR report classifies the facility as No Action Indicated (NAI).